Clinical trial · no report yet · Phase 3
CheckMate-67T
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- NCT04810078 ↗
- Active not recruiting
- Bristol-Myers Squibb
- 47 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 19 | |
| Podcasts | 15 | |
| YouTube | 13 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Have Received Prior Systemic Therapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- Nivolumab and rHuPH20; Nivolumab
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Arm C · Experimental
- Arm D · Experimental
- Enrollment
- 681
- Primary outcomes
- Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale
- Adjusted Geometric Mean of Nivolumab Trough Serum Concentration at Steady State (Cminss) on Original Scale
- Sponsor
- Bristol-Myers Squibb
- Start
- May 21, 2021
- Primary completion
- Jul 29, 2025
- Results posted
- Yes
- Registry record
- NCT04810078 · updated Sep 22, 2026
Publications
linked from the registry- Albiges L, Bourlon MT, Chacon M, Cutuli HJ, Chuken YAL, Zurawski B, Mota JM, Magri I, Burotto M, Luz M, de Menezes J, Ruiz EPY, Fu S, Richardet M, Valderrama BP, Maruzzo M, Bracarda S, Breckenridge M, Vezina HE, Rathod D, Yu Z, Zhao Y, Dixon M, Perumal D, George S. Subcutaneous versus intravenous nivolumab for renal cell carcinoma. Ann Oncol. 2025 Jan;36(1):99-107. doi: 10.1016/j.annonc.2024.09.002. Epub 2024 Sep 15. PubMed 39288844